MCRB

1.2406.77%
KC

Kurt C. Graves

Independent Director

Mr. Kurt C. Graves has been Independent Director of Seres Therapeutics, Inc. since November 10, 2015. He serves as Chairman, President & CEO since August 2023 and served as Executive Chairman at i2O Therapeutics, Inc. since August 2021 until August 2023. He was the Executive Chairman of Intarcia Therapeutics, Inc. since September 2010 until December 2020 and was its Chief Executive Officer and President since September 2010 until December 2020. He has served as its Director since 2012. Mr. Graves has been an independent consultant since October 2009. He has vast of business leadership experience in leading global pharmaceutical and biotech companies. He served as Executive Chairman of Biolex Therapeutics, Inc. since November 9, 2010 till March 2012. He served as the Chief Marketing Officer of Novartis Pharma AG. He served as an Executive Director and Business Unit Commercialization Leader at Astra Merck Pharmaceuticals. He has more than 25 years of U.S. and global general management experience in top-tier U.S. and European based pharmaceutical and biotech companies. He served as an Executive Vice President, Chief Commercial Officer and Head of Strategic Development at Novartis Pharmaceuticals Incorporated from July 2007 to October 2, 2009. He held various positions at Novartis Pharmaceuticals from January 1999 to June 2007, including U.S. General Manager, Head of Commercial Operations, Global Head of the General Medicines Business Unit and Chief Marketing Officer for the Pharmaceuticals division from September 2003 to June 2007. Mr. Graves served as the Head of General Medicines and Chief Marketing Officer of Pharmaceuticals at Novartis AG of Novartis India Ltd. Prior to that, he served as Senior Vice President & General Manager of U.S. Pharma & Commercial Operations; Vice President, Head of U.S. Marketing & Primary Care Franchises; and Vice President & Business Unit Head: Respiratory, GI, Dermatology and Bone Franchises. Prior to joining Novartis, he has played key leadership roles in building two highly successful early stage companies at Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. He served as Executive Vice President, Chief Commercial Officer and Head of Strategic Development at Vertex Pharmaceuticals Inc. from July 2007 to October 2009. He served as GI Business Unit Head of U.S. Gastrointestinal Franchise at Astra Pharmaceuticals, LP from 1997 to 1998. Prior to joining Novartis, Mr. Graves held various commercial and general management positions since 1990 at Merck and Astra/Merck Pharmaceuticals including U.S. GI Business Unit Head another multi-billion dollar business with responsibility for Prilosec(R), Nexium(R) and the Prilosec OTC alliance with P&G. From 1993 to 1997, he served in a variety of roles at Astra Merck Pharmaceuticals including Business Unit Commercialization Leader. He served as the Chairman of the Board of Radius Health, Inc. since May 2011 until March 23, 2020 and its Director since May 24, 2011 until March 23, 2020. He has been a Director of Pulmatrix Pharmaceuticals since May 2010. He had been an Independent Director of Achillion Pharmaceuticals, Inc. since June 2012 until January 28, 2020. He serves as a Director of Alevium Pharmaceuticals and Entra Therapeutics. He was also E&Y’s New England Entrepreneur of the Year in 2015. He served as a Director of Pulmatrix, Inc. since May 2010 until June 14, 2016. He served as a Director of Biolex Therapeutics, Inc. and SpringLeaf Therapeutics, Inc. He is a Global Industry Leader. Mr. Graves earned B.S. degree in Biology from Hillsdale College and has attended numerous Executive Leadership Programs at Harvard, Wharton School of Management and University of Michigan.

Positions